Psychopharmacology and Psychiatry Updates The SSRI-Anticoagulant Interaction: Evidence-Based Prescribing Strategies
9 snips
Feb 5, 2026 Paul Zarkowski, a consultation-liaison psychiatrist and academic, reviews a meta-analysis on SSRI plus anticoagulant bleeding risk. He outlines the pooled increased hazard and differences with direct oral anticoagulants. Age, sex, and baseline anticoagulant risk are discussed. Mechanisms of SSRI-related platelet effects and safer antidepressant alternatives are highlighted.
AI Snips
Chapters
Transcript
Episode notes
Elderly Patient Frames The Dilemma
- A 78-year-old woman on apixaban presents with classic depression and prompts concern about starting an SSRI.
- The case frames the clinical dilemma of treating depression while managing anticoagulation bleeding risk.
SSRI + Anticoagulant Raises Major Bleeding Risk
- A meta-analysis of ~98,000 patients found SSRIs plus oral anticoagulants raised major bleeding risk by about 35%.
- The pooled hazard ratio was 1.35 with a 95% CI of 1.14–1.58, indicating a significant increase.
Baseline Bleeding Risk And DOACs
- Baseline major bleed rates on warfarin run roughly 2–5% annually with fatal bleeds 0.5–1%.
- Direct oral anticoagulants (DOACs) generally lower major bleed risk compared with warfarin for common indications.